Wall Street Wire
Nuvectis Pharma’s NXP900 Shows Promising Efficacy in NSCLC Combination Therapy, Analysts See Significant Upside
A newly published study from the Cleveland Clinic’s Lerner Research Institute has added to the growing body of evidence supporting Nuvectis Pharma’s (NASDAQ: NVCT)* NXP900, a novel SRC/YES1 kinase inhibitor. The study, featured in Molecular Cancer Research, demonstrated that the combination of NXP900 with AstraZeneca’s blockbuster
